This New Drug May Be Even Stronger Than Ozempic For Weight Loss, Clinical Trial Shows - BI
Portfolio Pulse from Benzinga Newsbot
A clinical trial has shown that Mounjaro, a diabetes drug developed by Eli Lilly and Co. (NYSE:LLY), could be a more potent weight loss drug than Ozempic. The drug has shown potential in reducing the risk of chronic diseases and putting diabetes into remission. However, access to Mounjaro is limited due to its high cost and lack of insurance coverage.
June 24, 2023 | 11:03 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eli Lilly's diabetes drug Mounjaro could be a more potent weight loss drug than Ozempic, but access is limited due to high cost and lack of insurance coverage.
The clinical trial results show that Mounjaro has the potential to be a more potent weight loss drug than Ozempic, which could increase demand for the drug and boost Eli Lilly's revenues. However, the high cost and lack of insurance coverage may limit the drug's market penetration, potentially dampening the stock's short-term gains.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100